12 Results for "

SARS-CoV-2-IN-50

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "SARS-CoV-2-IN-50" in MCE Product Catalog:

Cat. No.: HY-154976
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-50 (Compound X77C) is a SARS-CoV-2 main protease (M Pro) inhibitor.. SARS-CoV-2-IN-50 has a high affinity to the catalytic site of M Pro .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-12473
CAS No.: 1523404-29-6
Purity:  99.81%
Target:  

PI3K SARS-CoV

Research Areas:  

Cancer

Vps34-IN-2 is a novel, potent and selective inhibitor of Vps34 with IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively . Vps34-IN-2 shows antiviral activity against SARS-CoV-2 (IC50 of 3.1 μM), HCoV-229E (IC50 of 0.7 μM) and HCoV-OC43 .
loading...
    loading...
Cat. No.: HY-172223
CAS No.: 56039-11-3
Synonyms: C3Guo
Target:  

SARS-CoV

Research Areas:  

Infection

3-Deazaguanosine (C3Guo) has potent antiviral activity against SARS-CoV-2 (EC50: 1.14 μM, CC50: >200 μM for Vero E6 cells). 3-Deazaguanosine prevents COVID-19 pneumonia .
loading...
    loading...
Cat. No.: HY-176440
Research Areas:  

Infection

BP-198 is an Mpro PROTAC degrader. BP-198 promotes the ubiquitination and degradation of Mpro. BP-198 has antiviral effects against SARS-CoV-2 (IC50: 11.8 μM) and has stronger activity against drug-resistant viruses .
loading...
    loading...
Cat. No.: HY-178772
CAS No.: 3038701-72-0
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC50 of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC50 s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC50 : 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research .
loading...
    loading...
Cat. No.: HY-161070
CAS No.: 877660-90-7
Research Areas:  

Infection

Antiviral agent 46 (compound 4) is a derivative of cannabidiol (CBD) with anti-SARS-CoV-2 (IC50: 1.90 μM) and ACE2 activity (IC50: 1.37 μM) .
loading...
    loading...
Cat. No.: HY-162414
CAS No.: 214221-82-6
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ) .
loading...
    loading...
Cat. No.: HY-156008
CAS No.: 3052692-38-0
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 M pro with an IC50 of 0.35 μM .
loading...
    loading...
Cat. No.: HY-155155
CAS No.: 1265624-68-7
Target:  

SARS-CoV Sigma Receptor

Research Areas:  

Infection

SARS-CoV-2-IN-57 (compound (+)-R-26) is a potent inhibitor of SARS-CoV-2 (IC50: 80 nM). SARS-CoV-2-IN-57 has high affinity for Sigma Receptor with Kis of 13.6 nM (S1R) and 14.4 nM (S2R) respectively .
loading...
    loading...
Cat. No.: HY-175015
CAS No.: 1800004-01-6
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2 Mpro-IN-46 (Compound 12) is a SARS-CoV-2 main protease inhibitor with an IC50 of ∼25 μM. SARS-CoV-2 Mpro-IN-46 has potent antiviral activity with low cytotoxicity against SARS-CoV-2 (IC50: 7.4 μM). SARS-CoV-2 Mpro-IN-46 can be used for coronaviruses COVID-19 research .
loading...
    loading...
Cat. No.: HY-162914
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-96 (compound 12b) is an inhibitor of HCoV-OC43 (EC50= 97 nM) and SARS-CoV-2 (EC50= 45 nM) and low cytotoxicity (CC50> 10 μM) in Huh7 cells .
loading...
    loading...
Cat. No.: HY-181661
Target:  

SARS-CoV Virus Protease

Research Areas:  

Infection

YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PL pro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PL pro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PL pro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection) .
loading...
    loading...
  • 1